# Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells

## TL;DR

Canagliflozin helps overcome progestin resistance in endometrial cancer by targeting specific signaling pathways linked to thyroid hormone receptor B deficiency.

## Contribution

Canagliflozin is shown to alleviate progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells.

## Key findings

- THRB deficiency in RL95-2 cells induced progestin resistance, which was overcome by canagliflozin.
- Canagliflozin reduced tumor growth in xenograft models and downregulated RARβ, RXRA, and CRABP2 expression.
- TRβ negatively regulates RARβ, while RARβ positively regulates CRABP2, contributing to progestin resistance.

## Abstract

Progestin resistance has emerged as a significant barrier to the conservative management of endometrial cancer (EC). The mechanisms underlying progestin resistance in endocrine therapy remain incompletely understood. Previous studies have suggested that silencing thyroid hormone receptor B (THRB) is associated with progestin resistance in EC cells.

THRB-knockout RL95-2 (THRB(−/−)/RL95-2) cells were constructed to investigate progestin resistance mechanisms. Cell proliferation and apoptosis were assessed in RL95-2 and THRB(−/−)/RL95-2 cells treated with canagliflozin (CANA), medroxyprogesterone acetate (MPA), and their combination using CCK-8, EdU, and flow cytometry assays. In vivo, nude mouse xenograft models were used to evaluate the efficacy of CANA and MPA. Transcriptomic and proteomic analyses were performed to identify pathways associated with progestin resistance. Molecular dynamics simulations, along with western blotting and immunohistochemistry were utilized to validate the targets of CANA. Electrophoretic mobility shift assays and dual luciferase reporter assays were employed to investigate the interactions between TRβ, RARβ, and CRABP2.

THRB(−/−)/RL95-2 cells were successfully constructed. CANA demonstrated a strong binding affinity for TRβ. Both MPA and CANA suppressed proliferation in RL95-2 cells, but MPA was ineffective in THRB(−/−)/RL95-2 cells, indicating that THRB deficiency induced progestin resistance. CANA significantly inhibited proliferation and promoted apoptosis in THRB(−/−)/RL95-2 cells. In vivo, CANA, either alone or in combination with MPA, significantly reduced tumor growth in xenograft models derived from both wild-type and THRB-knockout RL95-2 cells. Transcriptomic and proteomic analyses revealed that progestin resistance in EC was linked to the retinoic acid signaling pathways. Western blotting confirmed that the expressions of RARβ, RXRA and CRABP2 were significantly elevated in THRB(−/−)/RL95-2 cells. Treatment with CANA, alone or in combination with MPA, effectively reduced the expression of these proteins. Immunohistochemical analysis demonstrated that RARβ expression was significantly increased in uterine tissues from patients with progestin-insensitive EC or endometrial atypical hyperplasia. Electrophoretic mobility shift assays and dual luciferase reporter assays demonstrated that TRβ negatively modulated RARβ expression by binding to its promoter, while RARβ positively regulated CRABP2 expression.

THRB knockout activated retinoic acid pathway, leading to progestin resistance. CANA targeted RARβ and RXRA, downregulated CRABP2, restored BAX levels, and counteracted progestin resistance. The combination of CANA and MPA presented a novel strategy for alleviating progestin resistance and enhancing clinical efficacy.